Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

Cardiologist seeks answers about Trump’s health after MRI

After President Donald Trump told reporters he underwent an MRI—adding that the results were “perfect”—it remains unclear why, exactly, the scan was ordered in the first place.

heart drugs with stethoscope

New drug recall includes more than 140K bottles of popular statin

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

P‐waves can help identify Black patients prone to developing AFib

Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.

dental floss

Poor oral health tied to much higher risk of heart attack, stroke

Regularly going to the dentist, researchers added, may reduce cardiovascular risks by a significant margin.

'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk

These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

Daniel Addison, MD, Director of Translational Research in the Cardiology Division and Associate Director for Survivorship and Outcomes Research in the Harold C. Simmons Comprehensive Cancer Center. He also holds the Audre and Bernard Rapport Endowed Chair in Cardiovascular Research, UT Southwestern Medical Center. explains the health disparities and inequities involved in cardio-oncology.

How clinicians can combat health disparities in cardio-oncology

Researchers, for example, could improve disparities by performing their tests on more diverse groups of patients. Daniel Addison, MD, shared his perspective with Cardiovascular Business. 

approval regulations checkmark doctor

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.

How mental health can influence cardiovascular health

Different subtypes of depression are association with specific cardiometabolic diseases, according to new data out of the Netherlands.